Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD

NCT00749411 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Placebo
DRUG: GSK233705/GW642444

Sponsor

GlaxoSmithKline